News
Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego Topas Therapeutics today announced that it will present ...
HAMBURG, Germany, April 24, 2025--(BUSINESS WIRE)--Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac disease patients at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback